BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Watson Pharmaceuticals, Inc. (WPI) Confirms Court Decision Rejecting Teva Women's Health, Inc. (Formerly Known as Duramed Pharmaceuticals, Inc.) (TEVA)'s Motion to Prevent Launch of Generic SEASONIQUE(R)


6/17/2011 6:56:46 AM

PARSIPPANY, N.J., June 17, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The company is evaluating plans to launch the contraceptive product.

On March 25, 2011, Watson received a favorable decision from the United States Court of Appeals for the Federal Circuit that reversed and remanded for trial a March 31, 2010 summary judgment order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).

On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.

SEASONIQUE® is indicated for the prevention of pregnancy.

SEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:


Patty Eisenhaur


(862) 261-8141




Media:


Charlie Mayr


(862) 261-8030



SOURCE Watson Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES